Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis (Q26828622)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis	scientific article

Statements

scholarly article

1 reference

1 reference

20 May 2022

1 reference

PubMed publication ID

systematic review

1 reference

PubMed publication ID

comparative study

1 reference

PubMed publication ID

Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis (English)

1 reference

ankylosing spondylitis

1 reference

14 November 2020

monoclonal antibody

1 reference

27 September 2019

1 reference

15 August 2020

disease-modifying antirheumatic drug

1 reference

14 November 2020

biological products

1 reference

PubMed publication ID

author name string

Petra Baji

1

1 reference

Márta Péntek

2

1 reference

Sándor Szántó

3

1 reference

Pál Géher

4

1 reference

László Gulácsi

5

1 reference

Orsolya Balogh

6

1 reference

Valentin Brodszky

7

1 reference

language of work or name

1 reference

publication date

May 2014

1 reference

1 May 2014

8 references

13 March 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

15 August 2020

14 November 2020

20 May 2022

The European Journal of Health Economics

9 references

13 March 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

15 August 2020

14 November 2020

20 May 2022

15 Suppl 1

1 reference

S45-52

1 reference

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

7 April 2017

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

7 April 2017

Combination of direct and indirect evidence in mixed treatment comparisons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

7 April 2017

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Indirect comparison of anti-TNF-α agents for active ankylosing spondylitis: mixed treatment comparison of randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylos

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Bayesian methods for evidence synthesis in cost-effectiveness analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4046080

28 September 2017

The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0593-5

21 January 2018

Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0593-5

21 January 2018

Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0593-5

21 January 2018

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0593-5

21 January 2018

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0593-5

21 January 2018

A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis

1 reference

https://api.crossref.org/works/10.1007%2FS10198-014-0593-5

21 January 2018

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24832835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24832835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Indirect comparison of the effects of anti-TNF biological agents in patients with Ankylosing Spondylitis by means of a Mixed Treatment Comparison performed on efficacy data from published randomised, controlled trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/24832835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/24832835

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10198-014-0593-5

0 references

Dimensions Publication ID

0 references

PMC publication ID

1 reference

PubMed publication ID

1 reference

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26828622&oldid=2177275474"